Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers

The melanocortin-4 receptor agonist setmelanotide is now recommended for the treatment of genetic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in patients aged 6 years and older. Here, we describe the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubern, Beatrice, Lourdelle, Alexandre, Clément, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580505/
https://www.ncbi.nlm.nih.gov/pubmed/37908575
http://dx.doi.org/10.1210/jcemcr/luad041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580505/
https://www.ncbi.nlm.nih.gov/pubmed/37908575
http://dx.doi.org/10.1210/jcemcr/luad041

Ejemplares similares